PHASE II STUDY OF INTERMITTENT ERLOTINIB (E) PLUS CARBOPLATIN (C), PACLITAXEL (P) AND BEVACIZUMAB (B) AS FRONTLINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC): AVAFAST STUDY

被引：0
|
作者：
Cobo Dols, Manuel A. [1 ]
Blanco, Esperanza [2 ]
Bernabe, Reyes [3 ]
Fernandez, Inmaculada [4 ]
Inoriza, Angel [5 ]
Laura Ortega, Ana [6 ]
Valdivia, Javier [7 ]
机构：
[1] Hru Carlos Haya, Malaga, Spain
[2] Hosp Infanta Cristina, Badajoz, Spain
[3] Hosp Nuestra Senora De Valme, Seville, Spain
[4] Hosp De Jerez, Cadiz, Spain
[5] Hosp Juan Ramon Jimenez, Huelva, Spain
[6] Complejo Hosp De Jaen, Jaen, Spain
[7] Hosp Univ Virgen Nieves, Granada, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
ADVANCED NSCLC; Intermittent Erlotinib; Clinical Trial in Progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-052
引用
收藏
页码：S1213 / S1213
页数：1
相关论文
共 50 条
  • [21] A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
    Miura, Satoru
    Maemondo, Makoto
    Iwashima, Akira
    Harada, Toshiyuki
    Sugawara, Shunichi
    Kobayashi, Kunihiko
    Inoue, Akira
    Nakagawa, Taku
    Takiguchi, Yuichi
    Watanabe, Hiroshi
    Ishida, Takashi
    Terada, Masaki
    Kagamu, Hiroshi
    Gemma, Akihiko
    Yoshizawa, Hirohisa
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (02) : 227 - 234
  • [22] A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016)
    Satoru Miura
    Makoto Maemondo
    Akira Iwashima
    Toshiyuki Harada
    Shunichi Sugawara
    Kunihiko Kobayashi
    Akira Inoue
    Taku Nakagawa
    Yuichi Takiguchi
    Hiroshi Watanabe
    Takashi Ishida
    Masaki Terada
    Hiroshi Kagamu
    Akihiko Gemma
    Hirohisa Yoshizawa
    Investigational New Drugs, 2017, 35 : 227 - 234
  • [23] CLINICAL PROFILE AND PATTERNS OF PROGRESSION (PD) OF PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC) TREATED WITH FIRST LINE BEVACIZUMAB (B): AVVA STUDY
    De Castro, J.
    Garcia-Bueno, J. M.
    Domine, M.
    Saura, S.
    Garcia-Gomez, R.
    Sereno, M.
    Juan, O.
    Pujol, E.
    Rubio, B.
    Cobo, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 441 - 441
  • [24] A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation
    Akerley, Wallace
    Boucher, Kenneth
    Rich, Nathan
    Egbert, Lyle
    Harker, Graydon
    Bylund, Julie
    Van Duren, Terry
    Reddy, Chakravarthy
    LUNG CANCER, 2013, 79 (03) : 307 - 311
  • [25] Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Naito, Yoshiko
    Matsuo, Norikazu
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Ichiki, Masao
    Hoshino, Tomoaki
    ANTICANCER RESEARCH, 2018, 38 (06) : 3779 - 3784
  • [26] CLINICAL PROFILE AND PATTERNS OF PROGRESSION (PD) OF PATIENTS (PTS) WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSNSCLC) TREATED WITH FIRST LINE BEVACIZUMAB (B): AVVA STUDY
    de Castro, J.
    Domine, M.
    Garcia-Bueno, J. M.
    Saura, S.
    Garcia, R.
    Sereno, M.
    Juan, O.
    Pujol, E.
    Rubio, B.
    Cobo, M.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S74 - S74
  • [27] Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as first-line treatment for elderly patients with advanced non-squamous non-small cell lung cancer
    Takeoka, Hiroaki
    Yamada, Kazuhiko
    Ishii, Hidenobu
    Tokito, Takaaki
    Azuma, Koichi
    Naito, Yoshiko
    Matsuo, Norikazu
    Ichiki, Masao
    Hoshino, Tomoaki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [28] PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH CARBOPLATIN PLUS PACLITAXEL AS FIRST-LINE CHEMOTHERAPY FOR NON-SQUAMOUS NON-SMALL CELL LUNG CANCER WITH MALIGNANT PLEURAL EFFUSION
    Tamiya, Akihiro
    Tamiya, Motohiro
    Yamadori, Tadahiro
    Yasue, Tomomi
    Nakao, Keiko
    Shiroyama, Takayuki
    Asami, Kazuhiro
    Morishita, Naoko
    Suzuki, Hidekazu
    Okamoto, Norio
    Okishio, Kyoichi
    Kawaguchi, Tomoya
    Hirashima, Tomonori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1159 - S1160
  • [29] Phase II study of bevacizumab in combination with carboplatin plus paclitaxel as first-line chemotherapy for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, M.
    Tamiya, A.
    Asami, K.
    Okishio, K.
    Kawagchi, T.
    Suzuki, H.
    Okamoto, N.
    Kawase, I.
    Atagi, S.
    Hirashima, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S826 - S826
  • [30] Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion
    Tamiya, Motohiro
    Tamiya, Akihiro
    Suzuki, Hidekazu
    Taniguchi, Yoshihiko
    Katayama, Kanako
    Minomo, Shojiro
    Nakao, Keiko
    Takeuchi, Naoko
    Matsuda, Yoshinobu
    Naito, Yujiro
    Shiroyama, Takayuki
    Okamoto, Norio
    Okishio, Kyoichi
    Kumagai, Toru
    Atagi, Shinji
    Imamura, Fumio
    Hirashima, Tomonori
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (04) : 1106 - 1112
12345